A five-year study, called Mammo-50, that followed women aged 50 and older with a breast cancer diagnosis and surgery has been ...

Learn how individualized screening and prevention strategies can help reduce breast cancer risk. Discover key risk factors, ...

New research results now published from Lund University’s MASAI trial are even better than the initial findings from last ...

The MASAI trial reveals AI in mammography increases cancer detection by 29% and decreases radiologists' workload by 44%, ...

Hundreds of islanders ran, walked, or cycled 5km on Sunday 2 February in support of breast cancer charity ABC Jersey. | ITV News Channel ...

Delays blew out to four months after the critical service was impacted last year when one of only two providers servicing ...

In a challenging market environment, Atossa Genetics Inc . (NASDAQ:ATOS) stock has touched a 52-week low, reaching a price ...

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company with a market capitalization of $120 million and an impressive 13% gain over the past week, has announced ...

As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment.

This study evaluated the ability of low doses of (Z)-endoxifen to reduce mammographic breast density (MBD), an independent risk factor for breast cancer that also complicates early tumor detection.

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has reached its enrollment goal of 108,508 women, as announced today by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The study ...